Ignite Creation Date:
2024-05-06 @ 10:47 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03358472
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2017-11-27
Brief Title:
Pembrolizumab Plus Epacadostat Pembrolizumab Monotherapy and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma KEYNOTE-669ECHO-304
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2018-07-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-27
Completion Date Type:
ESTIMATED
First Submit Date:
2017-11-27
First Submit QC Date:
November 27 2017
Study First Post Date:
2017-11-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2019-09-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-26
Last Update Post Date:
2024-06-28
Last Update Post Date Type:
ACTUAL